Not finding it? Sign in to also search OpenAlex live.
-
#425 Felzartamab (anti-CD38) in patients with IgA Nephropathy—interim results from the IGNAZ study2024 Nephrology Dialysis Transplantation article Medicine Renal Diseases and Glomerulopathies cited by 1 patent
Jürgen Floege, Richard A. Lafayette, Jonathan Barratt, Brian S. Schwartz, Paul T. Manser, Uptal D. Patel, +6 more
13citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations -
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy2025 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access cited by 1 patent
Jürgen Floege, Richard A. Lafayette, Jonathan Barratt, Brian S. Schwartz, Paul T. Manser, Uptal D. Patel, +7 more
25citations -
Bimodal nanobody agents for cancer imaging and potential intraoperative guidance: a systematic review2026 Journal of Nanobiotechnology review Medicine Monoclonal and Polyclonal Antibodies Research Open access
Najaf Mammadbayli, Betül Altunay, Quim Peña, Dmytro Kobzev, Agnieszka Morgenroth, Masoud Sadeghzadeh, +4 more
3citations -
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Hans Jürgen Salwender, Michael Hundemer, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, +27 more
1citations -
Single-Cell Multiomic Profiling of Peripheral Blood Mononuclear Cells Reveals Immune Heterogeneity and Therapeutic Target Expression in IgAN2025 Journal of the American Society of Nephrology article Immunology and Microbiology T-cell and B-cell Immunology
Turgay Saritas, Felix Schreibing, Vivien Goepp, Teresa Maria Schreibing, Sikander Hayat, Rafael Kramann
0citations -
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Uta Bertsch, Roland R. Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, +26 more
162citations -
WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY2025 Kidney International Reports article Medicine Renal Diseases and Glomerulopathies Open access cited by 1 patent
Uptal D. Patel, Jürgen Flöge, Jonathan Barratt, Richard A. Lafayette, Brian S. Schwartz, Paul T. Manser, +5 more
2citations -
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno Valentin Sinn, Sibylle Loibl, Claus Alexander Hanusch, Dirk-Michael Zahm, Hans‐Peter Sinn, Michael Untch, +16 more
46citations
21 results